Better Health for All

ATAI Life Sciences' core business is focused on developing treatments for mental health disorders, demonstrating a strong positive health impact. Its investigational drug, BPL-003, showed rapid, robust, and durable antidepressant effects in a Phase 2b study for treatment-resistant depression, meeting primary and all key secondary endpoints.

The company's products do not generate revenue from harmful activities. In terms of safety, BPL-003 was well-tolerated in both Phase 2a (12 patients) and Phase 2b (193 patients) studies, with 99% of treatment-emergent adverse events being mild or moderate, and no drug-related serious adverse events or suicide-related safety signals reported. The company's focus on treatment-resistant depression and the investigation of BPL-003 for alcohol use disorder highlight a strong commitment to mental health initiatives and addiction mitigation. While BPL-003 is protected by granted US, UK, and European composition-of-matter patents, there is no information regarding the company's flexibility or approach to these patents in relation to global health needs. No specific data on R&D or capital allocation for health innovation is provided.

Fair Money & Economic Opportunity

ATAI Life Sciences N.V. is a biopharmaceutical company focused on developing treatments for mental health disorders.

Its core business does not involve lending, insuring, moving, or storing money for consumers. Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, profit reinvestment in community finance, financial literacy initiatives, debt burden ratio, geographic inclusion, and product simplicity for financial products, are not applicable to the company's operations.

Fair Pay & Worker Respect

ATAI Life Sciences demonstrates strong employee engagement, with an overall rating of 4.7 out of 5 stars on Glassdoor and 96% of employees indicating they would recommend working at the company.

This employee rating is 34% above the industry average for Pharmaceutical & Biotechnology. Additionally, 93% of employees rate the business outlook as positive. The company has no public record of substantiated labor-law or human-rights violations in the past three years. However, no quantitative data is available for living wage coverage, CEO-to-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, employee turnover rate, insecure contract share, or health insurance coverage.

Honest & Fair Business

ATAI Life Sciences provides a confidential and anonymous financial concern hotline for complaints regarding accounting, internal accounting controls, or auditing matters, as required by the SEC.

This hotline offers secure methods including email, a web form, and a phone line. Messages are encrypted and delivered to the Audit Committee, and a 14-16 digit code is provided for message status tracking.

Kind to Animals

ATAI Life Sciences uses animals for product testing.

A specific study involving R-ketamine, a compound from ATAI, used 297 rats (143 female, 154 male) across three European research centers. This study was approved by institutional animal care and use committees and national guidelines.

Planet-Friendly Business

The provided articles do not contain specific, quantifiable data points for ATAI.US across any of the Planet-Friendly Business KPIs. While Article 0 mentions a new platform company, TryptageniX, will develop environmentally friendly manufacturing methods to minimize ATAI's ecological footprint and ensure a sustainable supply chain in the future.

This is a forward-looking statement about a subsidiary's planned actions, not current performance or specific metrics for ATAI.US. Other articles discuss general industry trends, such as Scope 3 emissions or the increase in life sciences companies with SBTi targets, but these do not provide company-specific data for ATAI.US. Therefore, all KPIs are omitted due to a lack of explicit, actionable evidence.

Respect for Cultures & Communities

The provided articles do not contain specific, quantifiable evidence for any of the KPIs related to 'Respect for Cultures & Communities' for ATAI.US. While ATAI is mentioned as a contributor to the Indigenous Reciprocity Initiative, the articles do not provide details on the number of formal partnerships, the percentage of revenue reinvested in local community development or cultural heritage, or any other specific metrics required by the rubric.

General discussions about industry concerns or potential benefits of engagement are not considered direct evidence of company actions or outcomes.

Safe & Smart Tech

The company has a vulnerability management program in place.

Users are granted rights to access, correct, delete, limit processing, object to processing, data portability, and file a complaint with a supervisory authority. The company is subject to numerous state, federal, and foreign health, data privacy, and consumer protection laws and regulations, and adheres to major data protection regulations, ensuring transfers comply with legal standards, including using standard contractual clauses for transfers outside the EU.